EN
Zimmer Biomet's Knee Problem Has a Timeline Management Keeps Mentioning
Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Part 2.1: Price Behavior Around Earnings
Zimmer Biomet typically reports before market open, meaning Day 0 represents the first reaction session and Day +1 captures follow-through trading.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-08-05 | +$2.35 (+2.45%) | $5.02 (5.24%) | -$0.97 (-0.99%) | $4.24 (4.32%) |
| 2026-04-28 | -$9.79 (-10.57%) | $7.29 (7.87%) | -$2.73 (-3.30%) | $2.85 (3.44%) |
| 2026-02-10 | +$1.67 (+1.86%) | $4.18 (4.65%) | +$4.21 (+4.61%) | $5.43 (5.94%) |
| 2025-11-05 | -$15.63 (-15.15%) | $8.10 (7.85%) | +$0.96 (+1.10%) | $3.59 (4.10%) |
| 2025-08-07 | +$7.28 (+7.99%) | $6.93 (7.60%) | +$0.83 (+0.84%) | $2.72 (2.76%) |
| 2025-05-05 | -$11.90 (-11.62%) | $9.90 (9.67%) | +$1.79 (+1.98%) | $2.82 (3.12%) |
| 2025-02-06 | -$5.56 (-5.14%) | $5.63 (5.20%) | -$1.76 (-1.71%) | $3.37 (3.28%) |
| 2024-10-30 | +$5.93 (+5.71%) | $2.82 (2.72%) | -$2.89 (-2.63%) | $3.11 (2.83%) |
| Avg Abs Move | 7.56% | 6.35% | 2.14% | 3.72% |
Historical price behavior shows significant volatility around earnings releases, with an average absolute Day 0 move of 7.56% and Day 0 range of 6.35%. The most recent report on August 5, 2026 produced a relatively modest +2.45% Day 0 move, well below the historical average, suggesting the market may have been positioned for the beat. However, earlier reports in 2026 and 2025 delivered much larger swings—including a -10.57% drop on April 28, 2026 and a dramatic -15.15% decline on November 5, 2025.
The Day +1 follow-through averages 2.14%, indicating that initial reactions often extend into the next session. Notably, several reports show reversals between Day 0 and Day +1 (such as the November 2025 report, which dropped -15.15% on Day 0 but recovered +1.10% on Day +1), suggesting that knee-jerk reactions sometimes prove overdone. The 3.72% average Day +1 range indicates continued active trading as investors digest the details.
Part 2.2: Options Market Expected Move
| Metric | Value |
|---|---|
| Expiration Date | 11/20/26 (DTE 17) |
| Expected Move | $6.84 (7.05%) |
| Expected Range | $90.22 to $103.90 |
| Implied Volatility | 44.06% |
The options market is pricing an expected move of 7.05% for the November 20 expiration, which aligns closely with the 7.56% average historical Day 0 move. This suggests options traders are anticipating typical volatility rather than an outsized reaction, despite the recent pattern of large earnings swings.
Part 3: What Analysts Are Saying
Analysts maintain a cautious stance on Zimmer Biomet, with the consensus rating at 3.45 (Hold) and a mean price target of $105.46—implying 8.7% upside from the current price of $97.06. The rating distribution shows limited conviction: among 29 analysts covering the stock, 7 rate it Strong Buy, 1 Moderate Buy, 20 Hold, and 1 Strong Sell. The dominance of Hold ratings (69% of coverage) reflects uncertainty about the company's ability to accelerate growth.
Sentiment has deteriorated over the past month, with one analyst downgrading from Hold to Strong Sell. The average recommendation edged slightly lower from 3.46 one month ago to 3.45 currently, while the number of Hold ratings increased from 19 to 20. This subtle shift suggests growing caution as the sequential earnings decline becomes more apparent.
The price target range is wide, spanning from a low of $87.00 to a high of $125.00, indicating significant disagreement about the company's valuation. The $105.46 mean target sits well above the current price, but the fact that EPS estimates have remained flat over the past 60 days suggests analysts are waiting for proof of execution before raising their outlooks. The concentration of Hold ratings and deteriorating sentiment signal that most analysts want to see evidence of sustained growth and successful innovation monetization before turning more bullish.
Part 4: Technical Picture
Zimmer Biomet enters earnings with strengthening technical momentum, as the Barchart Technical Opinion has surged to 88% Buy from 72% one week ago and just 24% one month ago. This dramatic improvement reflects accelerating bullish sentiment heading into the report.
Timeframe Analysis:
- Short-term (50% Buy): Moderate buy signal indicates near-term momentum is positive but not overwhelming
- Medium-term (100% Buy): Strong buy signal across all medium-term indicators suggests solid intermediate-term trend strength
- Long-term (100% Buy): Maximum bullish reading reflects robust longer-term uptrend momentum
Trend Characteristics: The combination of Average strength and Average direction suggests a steady, sustainable uptrend rather than an overheated or parabolic move—a constructive setup heading into earnings.
The stock is trading above all major moving averages, including the 5-day ($96.56), 10-day ($96.85), 20-day ($94.57), 50-day ($94.69), 100-day ($93.81), and 200-day ($91.72). This alignment indicates strong technical support across all timeframes.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $96.56 | 50-Day MA | $94.69 |
| 10-Day MA | $96.85 | 100-Day MA | $93.81 |
| 20-Day MA | $94.57 | 200-Day MA | $91.72 |
The current price of $97.06 sits comfortably above the rising 200-day moving average at $91.72, providing a cushion of approximately 5.8% to that key long-term support level. The stock's position above all moving averages and the recent surge in technical opinion to 88% Buy suggest the setup is supportive heading into earnings. However, with the options market pricing a 7.05% move and historical volatility averaging 7.56%, traders should be prepared for significant post-earnings price action that could test these technical levels. The 52-week range positioning near the middle (between $87.00 and $125.00 based on analyst targets) provides room for movement in either direction depending on results and guidance.